2024 levels generally holding at pandemic-level lows across substances

Systematic review and meta-analysis show fewer depressive symptoms in association with higher step counts

CBD did not meet primary end point comparing preingestion to postingestion anxiety, but resulted in lower anxiety levels

Findings seen despite the large number of justice-involved people and their unique health needs

Results also showed age-adjusted rate of drug overdose deaths decreased from 2022 to 2023, after increasing over 20 years

Findings show persistent posttreatment genital hypoesthesia among sexual and gender minority youth with history of antidepressant use

Findings seen for both all-cause and cause-specific hospital admissions

Significantly increased risks seen for major adverse cardiovascular events and any cardiovascular condition

taVNS significantly reduces insomnia severity and is associated with sustained benefits over 20 weeks